Literature DB >> 1777961

Use of antioxidant therapy in shock and trauma.

Y K Youn1, C LaLonde, R Demling.   

Abstract

Antioxidant therapy can be defined in the clinical setting as any process that prevents or decreases oxidant injury. A number of common clinical approaches to the shock and trauma patient can be considered as preventing oxidant damage. In fact, their beneficial effects may be related more to antioxidant activity than is currently recognized. In addition, there are a number of new drugs, many of them already clinically used for other indications, that have antioxidant and general inflammatory activity and are either undergoing or are about to undergo clinical testing. The era of antioxidant therapy has arrived.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1777961

Source DB:  PubMed          Journal:  Circ Shock        ISSN: 0092-6213


  6 in total

1.  Calpain inhibitor I reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; I Serraino; L Dugo; D Britti; G Mazzullo; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 2.  Prospects for the use of antioxidant therapies.

Authors:  S R Maxwell
Journal:  Drugs       Date:  1995-03       Impact factor: 9.546

3.  Endothelial dysfunction in a rat model of endotoxic shock. Importance of the activation of poly (ADP-ribose) synthetase by peroxynitrite.

Authors:  C Szabó; S Cuzzocrea; B Zingarelli; M O'Connor; A L Salzman
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

Review 4.  [Significance of selenium in intensive care medicine. Clinical studies of patients with SIRS/sepsis syndrome].

Authors:  R Gärtner; M Angstwurm
Journal:  Med Klin (Munich)       Date:  1999-10-15

5.  Beneficial effects of raxofelast (IRFI 016), a new hydrophilic vitamin E-like antioxidant, in carrageenan-induced pleurisy.

Authors:  S Cuzzocrea; G Costantino; E Mazzon; A P Caputi
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 6.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.